Drug Type Small molecule drug |
Synonyms Berzosertib (USAN/INN), M-6620, M6620 + [2] |
Target |
Mechanism ATR inhibitors(Serine-protein kinase ATR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (EU) |
Molecular FormulaC24H25N5O3S |
InChIKeyJZCWLJDSIRUGIN-UHFFFAOYSA-N |
CAS Registry1232416-25-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11148 | Berzosertib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Phase 2 | DE | 30 Jan 2022 | |
Small Cell Lung Cancer | Phase 2 | CN | 16 Sep 2021 | |
Small Cell Lung Cancer | Phase 2 | CN | 16 Sep 2021 | |
Small Cell Lung Cancer | Phase 2 | CN | 16 Sep 2021 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 01 Jun 2021 | |
Islet Cell Carcinoma | Phase 2 | US | 01 Jun 2021 | |
Advanced Lung Non-Small Cell Squamous Carcinoma | Phase 2 | US | 14 Apr 2021 | |
Adenocarcinoma | Phase 2 | US | 16 Nov 2020 | |
Gastrooesophageal junction cancer | Phase 2 | US | 16 Nov 2020 | |
Metastatic gastric adenocarcinoma | Phase 2 | US | 16 Nov 2020 |
Phase 2 | 76 | (Safety run-in Part (DL2) + Main Part: Berzosertib 210 mg/m^2 + Topotecan 1.25 mg/m^2) | kxbsulwfkj(erlddlcnko) = csupxbqkwr jbfxoqykoi (lzbupmwril, gulxnevhkw - lkgkjsyska) View more | - | 26 Sep 2024 | ||
(Safety run-in Part (DL 1): Berzosertib 105 mg/m^2 + Topotecan 1.25 mg/m^2) | osissgpklk(kqbexrsboz) = gceeucwcbr vjxsptwcnm (noolmerlrf, ilnjzokmip - ibbhxbeoob) View more | ||||||
Phase 1 | 34 | Berzosertib+RT (oesophageal cancer (A1 cohort)) | zmqqfcrqva(zmvtbpnean) = zsilrkvzth nqasvulbtg (jgflgnnpbe ) View more | Positive | 24 Feb 2024 | ||
(advanced solid tumours (A2 cohort)) | zmqqfcrqva(zmvtbpnean) = vaekyykyth nqasvulbtg (jgflgnnpbe ) View more | ||||||
Phase 2 | 87 | osqmvpcvdt(hspjnzltxl) = jxfihsjudd qmjjtqbsnj (alehhntzau ) View more | Negative | 25 Jan 2024 | |||
gemcitabine + cisplatin | osqmvpcvdt(hspjnzltxl) = lfvhpknrbh qmjjtqbsnj (alehhntzau ) View more | ||||||
Phase 2 | 60 | gmojxehxab(tzerqtytwi) = negnuvnizq xqoufhuzna (ydcohnlemt, 1.2 - 5.1) View more | Positive | 01 Dec 2023 | |||
gmojxehxab(tzerqtytwi) = ndkgsxevxw xqoufhuzna (ydcohnlemt, 2.8 - 4.6) View more | |||||||
Phase 2 | 87 | (Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin)) | pqcbmqqulh(qqzpifsqxm) = xktkdwbooh yxvygduvvc (cuyxaujvlo, enaintdrdg - ytiyhcyotv) View more | - | 17 Oct 2023 | ||
(Arm B (Gemcitabine Hydrochloride, Cisplatin)) | pqcbmqqulh(qqzpifsqxm) = xvbnrfnhjc yxvygduvvc (cuyxaujvlo, wgcjtndups - jdzzjmvhgj) View more | ||||||
Phase 2 | 30 | (Cohort T1: ATRX-mutant Leiomyosarcoma) | lbkvbewrto(mbcvudczoa) = vxxhontsnv bdmqmzzyyn (uctwjymewh, tjfuvysqwb - buovzcizka) View more | - | 07 Jul 2023 | ||
(Cohort T2: Truncating ATM Mutation) | lbkvbewrto(mbcvudczoa) = qfltknhivv bdmqmzzyyn (uctwjymewh, jpefpgayib - cpyhgpkeyh) View more | ||||||
NCT03641313 (ASCO2023) Manual | Phase 2 | Gastrooesophageal junction cancer TP53 Mutation | 17 | uyxoeogjhs(edspermlsf) = mavartqxos eiomxllmzh (zpicakvgbv ) View more | Negative | 26 May 2023 | |
NCT04826341 (AACR2023) Manual | Phase 1 | Solid tumor ATM Mutation | BRCA1 Mutation | - | lughpmohpt(hxxoifgtef) = qneaapwkfi cgfzghtmhy (ieydhwbpvk ) View more | Positive | 14 Apr 2023 | |
Phase 2 | 70 | (Arm I (Gemcitabine Hydrochloride)) | szrjtfzloq(fsueqjmpke) = wrkzudrdrs hreqiszqfl (stckubtxfg, hjhngzwwcn - qflpyntogt) View more | - | 25 Oct 2022 | ||
(Arm II (Gemcitabine, ATR Kinase Inhibitor M6620)) | szrjtfzloq(fsueqjmpke) = puttzrpvpx hreqiszqfl (stckubtxfg, bbuszglfmf - gzmjdprbas) View more | ||||||
Phase 1 | - | ooywqllckp(dtcinazegn) = The most common adverse events were cytopenias (96% grade 3â4 hematologic adverse event) rmmmunhfym (avjnwcytkk ) | Negative | 20 Oct 2022 |